Efficacy of inhibitor eradication according to selected clinical variables and first-line immunosuppressant treatment
| Variable . | CR n/N (%) . | P . | Days until CR Median (IQR) . | P . |
|---|---|---|---|---|
| Age, y | ||||
| ≤65 | 28/34 (82.3) | .789 | 55 (26-89) | .662 |
| >65 | 82/97 (84.5) | 45 (28-83) | ||
| Sex | ||||
| Female | 44/57 (77.2) | .049 | 41 (29-83) | .798 |
| Male | 67/74 (90.5) | 46 (29-86) | ||
| FVIII:C | ||||
| <1 IU/dL | 26/33 (78.8) | .260 | 47 (31-84) | .420 |
| ≥1 IU/dL | 76/87 (87.4) | 42 (23-86) | ||
| Inhibitor | ||||
| ≤20 BU/mL | 79/83 (95.2) | .005 | 38 (22-67) | .001 |
| >20 BU/mL | 41/52 (78.8) | 62 (41-90) | ||
| Underlying disease | ||||
| Idiopathic | 46/54 (85.2) | 1.000 | 49 (31-74) | .759 |
| Others | 65/77 (84.4) | 45 (28-93) | ||
| Autoimmune | 32/40 (80.0) | .429 | 43 (30-77) | .722 |
| Others | 79/91 (86.8) | 49 (26-87) | ||
| Neoplasia | 15/15 (100) | .125 | 41 (28-89) | .932 |
| Others | 96/116 (82.8) | 45 (29-85) | ||
| Postpartum | 6/6 (100) | .590 | 65 (22-318) | .680 |
| Others | 105/125 (84.0) | 45 (30-83) | ||
| First-line IST choice | ||||
| Steroids | 15/22 (68.2) | .049 | 30 (15-214) | .503 |
| Other IST choices | 95/109 (87.2) | 47 (31-82) | ||
| Steroids + CFX | 54/61 (88.5) | .235 | 53 (31-82) | .491 |
| Other IST choices | 56/70 (80.0) | 41 (25-89) | ||
| Steroids + CNI | 13/16 (81.2) | .721 | 45 (30-73) | .815 |
| Other IST choices | 97/115 (84.3) | 45 (28-84) | ||
| Rituximab-based regimens | 28/32 (87.5) | .782 | 42 (26-84) | .929 |
| Other IST choices | 82/99 (82.8) | 49 (29-85) |
| Variable . | CR n/N (%) . | P . | Days until CR Median (IQR) . | P . |
|---|---|---|---|---|
| Age, y | ||||
| ≤65 | 28/34 (82.3) | .789 | 55 (26-89) | .662 |
| >65 | 82/97 (84.5) | 45 (28-83) | ||
| Sex | ||||
| Female | 44/57 (77.2) | .049 | 41 (29-83) | .798 |
| Male | 67/74 (90.5) | 46 (29-86) | ||
| FVIII:C | ||||
| <1 IU/dL | 26/33 (78.8) | .260 | 47 (31-84) | .420 |
| ≥1 IU/dL | 76/87 (87.4) | 42 (23-86) | ||
| Inhibitor | ||||
| ≤20 BU/mL | 79/83 (95.2) | .005 | 38 (22-67) | .001 |
| >20 BU/mL | 41/52 (78.8) | 62 (41-90) | ||
| Underlying disease | ||||
| Idiopathic | 46/54 (85.2) | 1.000 | 49 (31-74) | .759 |
| Others | 65/77 (84.4) | 45 (28-93) | ||
| Autoimmune | 32/40 (80.0) | .429 | 43 (30-77) | .722 |
| Others | 79/91 (86.8) | 49 (26-87) | ||
| Neoplasia | 15/15 (100) | .125 | 41 (28-89) | .932 |
| Others | 96/116 (82.8) | 45 (29-85) | ||
| Postpartum | 6/6 (100) | .590 | 65 (22-318) | .680 |
| Others | 105/125 (84.0) | 45 (30-83) | ||
| First-line IST choice | ||||
| Steroids | 15/22 (68.2) | .049 | 30 (15-214) | .503 |
| Other IST choices | 95/109 (87.2) | 47 (31-82) | ||
| Steroids + CFX | 54/61 (88.5) | .235 | 53 (31-82) | .491 |
| Other IST choices | 56/70 (80.0) | 41 (25-89) | ||
| Steroids + CNI | 13/16 (81.2) | .721 | 45 (30-73) | .815 |
| Other IST choices | 97/115 (84.3) | 45 (28-84) | ||
| Rituximab-based regimens | 28/32 (87.5) | .782 | 42 (26-84) | .929 |
| Other IST choices | 82/99 (82.8) | 49 (29-85) |
CR was considered when FVIII:C was ≥50%, the inhibitor was undetectable and no clinical manifestations related with AH were observed. Missing data were not considered. Some patients had more than 1 underlying disease/condition. Fisher’s exact or Mann-Whitney tests were used.
CFX, cyclophosphamide; CNI, calcineurin inhibitors.